HIV Citation List: September 30, 2011 - October 13, 2011

Pubmed citations

1. Selective inhibition of Human Immunodeficiency Virus type 1 (HIV-1) by a novel family of tricyclic nucleosides. Bonache, M.C., A. Cordeiro, E. Quesada, E. Vanstreels, D. Daelemans, M.J. Camarasa, J. Balzarini, and A. San-Felix, Antiviral Research, 2011. 92(1): p. 37-44; PMID[ 21600933].
[PubMed]. HIV_0930-101311.

2. Inhibition of HIV-1 Reverse Transcriptase, Toxicological and Chemical Profile of Calophyllum brasiliense Extracts from Chiapas, Mexico. Cesar, G.Z., M.G. Alfonso, M.M. Marius, E.M. Elizabeth, C.B. Angel, H.R. Maira, C.L. Guadalupe, J.E. Manuel, and R.C. Ricardo, Fitoterapia, 2011. 82(7): p. 1027-1034; PMID[ 21723379].
[PubMed]. HIV_0930-101311.

3. Anti-AIDS Agents 86. Synthesis and anti-HIV Evaluation of 2',3' -Seco-3'-nor DCP and DCK Analogues. Chen, Y., M. Cheng, F.Q. Liu, P. Xia, K. Qian, D. Yu, Y. Xia, Z.Y. Yang, C.H. Chen, S.L. Morris- Natschke, and K.H. Lee, European Journal of Medicinal Chemistry, 2011. 46(10): p. 4924-4936; PMID[ 21864952].
[PubMed]. HIV_0930-101311.

4. 3-Hydroxy-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-ones as New HIV-1 Integrase Inhibitors WO2011046873 A1. Cotelle, P., Expert Opinion on Therapeutic Patents, 2011. [Epub ahead of print]; PMID[ 21974685].
[PubMed]. HIV_0930-101311.

5. Dimethyl Fumarate , an Immune Modulator and Inducer of the Antioxidant Response, Suppresses HIV Replication and Macrophage-Mediated Neurotoxicity: A Novel Candidate for HIV Neuroprotection .   Cross, S.A., D.R. Cook, A.W. Chi, P.J. Vance, L.L. Kolson , B.J. Wong, K.L. Jordan- Sciutto , and D.L. Kolson , Journal of Immunology, 2011. [Epub ahead of print]; PMID[ 21976775].
[PubMed]. HIV_0930-101311.

6. 4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a Prototype to Develop Dual Inhibitors of HIV-1 Integration Process. De Luca, L., R. Gitto , F. Christ, S. Ferro, S. De Grazia , F. Morreale , Z. Debyser , and A. Chimirri , Antiviral Research, 2011. 92(1): p. 102-107; PMID[ 21767569].
[PubMed]. HIV_0930-101311.

7. Broad-spectrum Aptamer Inhibitors of HIV Reverse Transcriptase Closely Mimic Natural Substrates. Ditzler, M.A., D. Bose, N. Shkriabai, B. Marchand, S.G. Sarafianos, M. Kvaratskhelia, and D.H. Burke, Nucleic Acids Research, 2011. 39(18): p. 8237-8247; PMID[ 21727088].
[PubMed]. HIV_0930-101311.

8. An anti-HIV-1 Compound that Increases Steady-state Expression of Apoplipoprotein B mRNA-editing Enzyme-catalytic Polypeptide-like 3G. Ejima, T., M. Hirota, T. Mizukami, M. Otsuka, and M. Fujita, International Journal of Molecular Medicine, 2011. 28(4): p. 613-616; PMID[ 21725586].
[PubMed]. HIV_0930-101311.

9. Susceptibility of HIV Type 2 Primary Isolates to CCR5 and CXCR4 Monoclonal Antibodies, Ligands, and Small Molecule Inhibitors. Espirito-Santo, M., Q. Santos-Costa, M. Calado, P. Dorr, and J.M. Azevedo -Pereira, AIDS Research and Human Retroviruses, 2011. [Epub ahead of print]; PMID[ 21902586].
[PubMed]. HIV_0930-101311.

10. Design and Synthesis of Conformationally Constrained Inhibitors of Non-Nucleoside Reverse Transcriptase. Gomez, R., S. Jolly, T.M. Williams, J.P. Vacca, M. Torrent, G. McGaughey, M.T. Lai, P.J. Felock, V. Munshi, D. Distefano, J.A. Flynn, M.D. Miller, Y. Yan, J.C. Reid, R. Sanchez, Y. Liang, B. Paton, B.L. Wan, and N.J. Anthony, Journal of Medicinal Chemistry, 2011. [Epub ahead of print]; PMID[ 21985673].
[PubMed]. HIV_0930-101311.

11. Nuclear Receptor Signaling Inhibits HIV-1 Replication in Macrophages through Multiple trans-Repression Mechanisms. Hanley, T.M. and G.A. Viglianti, Journal of Virology, 2011. 85(20): p. 10834-10850; PMID[ 21849441].
[PubMed]. HIV_0930-101311.

12. Synthesis of 1-Benzyl-3-(3,5-dimethylbenzyl)uracil Derivatives with Potential anti-HIV Activity. Isono, Y., N. Sakakibara, P. Ordonez, T. Hamasaki, M. Baba, M. Ikejiri, and T. Maruyama, Antiviral Chemistry & Chemotherapy, 2011. 22(2): p. 57-65; PMID[ 21984685].
[PubMed]. HIV_0930-101311.

13. Efficient Discovery of Potent Anti-HIV Agents Targeting the Tyr181Cys Variant of HIV Reverse Transcriptase. Jorgensen, W.L., M. Bollini, V.V. Thakur, R.A. Domaoal, K.A. Spasov, and K.S. Anderson, Journal of the American Chemical Society, 2011. 133(39): p. 15686-15696; PMID[ 21853995].
[PubMed]. HIV_0930-101311.

14. Enantioselective Total Synthesis of the Potent anti-HIV Nucleoside EFdA. Kageyama, M., T. Nagasawa, M. Yoshida, H. Ohrui, and S. Kuwahara, Organic Letters, 2011. 13(19): p. 5264-5266; PMID[ 21888325].
[PubMed]. HIV_0930-101311.

15. Design and Synthesis of Carbocyclic Versions of Furanoid Nucleoside phosphonic acid Analogues as Potential anti-HIV Agents. Kim, E., G.H. Shen, and J.H. Hong, Nucleosides, Nucleotides & Nucleic Acids, 2011. 30(10): p. 798-813; PMID[ 21967290].
[PubMed]. HIV_0930-101311.

16. Telaprevir: Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C. Klibanov, O.M., S.H. Williams, L.S. Smith, J.L. Olin, and S.B. Vickery, Pharmacotherapy, 2011. 31(10): p. 951-974; PMID[ 21950642].
[PubMed]. HIV_0930-101311.

17. Synthesis of Novel 6'-Spirocyclopropyl-5'-norcarbocyclic adenosine phosphonic acid Analogues as Potent anti-HIV Agents. Liu, L.J., E. Kim, and J.H. Hong, Nucleosides, Nucleotides & Nucleic Acids, 2011. 30(10): p. 784-797; PMID[ 21967289].
[PubMed]. HIV_0930-101311.

18. Thiated Derivatives of 2',3'-Dideoxy-3'-fluorothymidine: Synthesis, in Vitro anti-HIV-1 Activity and Interaction with Recombinant Drug Resistant HIV-1 Reverse Transcriptase Forms. Miazga, A., F. Hamy, S. Louvel, T. Klimkait, Z. Pietrusiewicz, A. Kurzynska-Kokorniak, M. Figlerowicz, P. Winska, and T. Kulikowski, Antiviral Research, 2011. 92(1): p. 57-63; PMID[ 21683097].
[PubMed]. HIV_0930-101311.

19. Synthesis and in Vitro Activity of Novel N-3 Acylated TSAO-T Compounds Against HIV-1 and HCV. Moura, M., S. Josse, A.N. Van Nhien, C. Fournier, G. Duverlie, S. Castelain, E. Soriano, J. Marco- Contelles, J. Balzarini, and D. Postel, European Journal of Medicinal Chemistry, 2011. 46(10): p. 5046-5056; PMID[ 21880398].
[PubMed]. HIV_0930-101311.

20. 1-[2-(2-Benzoyl- and 2-Benzylphenoxy)ethyl]uracils as Potent anti-HIV-1 Agents. Novikov, M.S., O.N. Ivanova, A.V. Ivanov, A.A. Ozerov, V.T. Valuev -Elliston, K. Temburnikar, G.V. Gurskaya, S.N. Kochetkov, C. Pannecouque, J. Balzarini, and K.L. Seley-Radtke, Bioorganic & Medicinal Chemistry, 2011. 19(19): p. 5794-5802; PMID[ 21903401].
[PubMed]. HIV_0930-101311.

21. Design, Synthesis and Biological Evaluation of Optically Pure Functionalized spiro [ 5,5]Undecane-1,5,9-triones as HIV-1 Inhibitors. Ramachary, D.B., Y.V. Reddy, A. Banerjee, and S. Banerjee, Organic & Biomolecular Chemistry, 2011. 9(21): p. 7282-7286; PMID[ 21915419].
[PubMed]. HIV_0930-101311.

22. Phenotypic Susceptibility of HIV-2 to Raltegravir: Integrase Mutations Q148R and N155H Confer Raltegravir Resistance. Smith, R.A., D.N. Raugi, N.B. Kiviat, S.E. Hawes, J.I. Mullins, P.S. Sow, and G.S. Gottlieb, AIDS, 2011. [Epub ahead of print]; PMID[ 21971360].
[PubMed]. HIV_0930-101311.

23. Binding of Novel Fullerene Inhibitors to HIV-1 Protease: Insight through Molecular Dynamics and Molecular Mechanics Poisson-Boltzmann Surface Area Calculations. Tzoupis, H., G. Leonis, S. Durdagi, V. Mouchlis, T. Mavromoustakos, and M.G. Papadopoulos, Journal of Computer-Aided Molecular Design, 2011. [Epub ahead of print]; PMID[ 21969102].
[PubMed]. HIV_0930-101311.

24. Designing Hypothesis of Substituted Benzoxazinones as HIV-1 Reverse Transcriptase Inhibitors: QSAR Approach. Veerasamy, R., D.K. Subramaniam, O.C. Chean, and N.M. Ying, Journal of Enzyme Inhibition and Medicinal Chemistry, 2011. [Epub ahead of print]; PMID[ 21961709].
[PubMed]. HIV_0930-101311.

25. Arylazolylthioacetanilide. Part 8(): Design, Synthesis and Biological Evaluation of Novel 2-(2-(2,4 -Dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N- arylacetamides as Potent HIV-1 Inhibitors. Zhan, P., X. Chen, X. Li, D. Li, Y. Tian, W. Chen, C. Pannecouque, E. De Clercq, and X. Liu, European Journal of Medicinal Chemistry, 2011. 46(10): p. 5039-5045; PMID[ 21872971].
[PubMed]. HIV_0930-101311.

26. Ionic Derivatives of Betulinic acid as Novel HIV-1 Protease Inhibitors. Zhao, H., S.S. Holmes, G.A. Baker, S. Challa, H.S. Bose, and Z. Song, Journal of Enzyme Inhibition and Medicinal Chemistry, 2011. [Epub ahead of print]; PMID[ 21985312].
[PubMed]. HIV_0930-101311.

27. Metabolism of Novel anti-HIV Agent 3-Cyanomethyl-4-methyl-DCK by Human liver Microsomes and Recombinant CYP Enzymes. Zhuang, X.M., J.T. Deng, H. Li, W.L. Kong, J.X. Ruan, and L. Xie, Acta Pharmacologica Sinica 2011. 32(10): p. 1276-1284; PMID[ 21970838].
[PubMed]. HIV_0930-101311.

ISI Web of Knowledge citations:

28. Rationally Designed Interfacial Peptides Are Efficient In Vitro Inhibitors of HIV-1 Capsid Assembly with Antiviral Activity. Bocanegra, R.N., M Domenech, R Lopez, I Abian, O Rodriguez- Huete, A Cavasotto, CN Velazquez- Campoy, A Gomez, J Martinez, MA Neira, JL Mateu, MG, Plos One, 2011. 6(9); ISI[ 000294802800013].
[WOS]. HIV_0930-101311.

29. Synthesis of the Anti-HIV Agent (-)- Hyperolactone C by Using Oxonium Ylide Formation-Rearrangement. Hodgson, D.M. and S. Man, Chemistry-a European Journal, 2011. 17(35): p. 9731-9737; ISI[ 000295001100024].
[WOS]. HIV_0930-101311.

30. Multisite lambda Dynamics for Simulated Structure-Activity Relationship Studies. Knight, J.L. and Brooks, Journal of Chemical Theory and Computation, 2011. 7(9): p. 2728-2739; ISI[ 000294790400010].
[WOS]. HIV_0930-101311.

31. High-throughput Assay to Identify Inhibitors of Vpu -mediated down-regulation of Cell Surface BST-2. Zhang, Q.L., ZL Mi, ZY Li, XY Jia, PP Zhou, JM Yin, X You, XF Yu, LY Guo, F Ma, J Liang, C Cen, S, Antiviral Research, 2011. 91(3): p. 321-329; ISI[ 000294936800014].
[WOS]. HIV_0930-101311.

32. Zinc-finger Antiviral Protein Inhibits HIV-1 Infection by Selectively Targeting Multiply Spliced Viral mRNAs for Degradation. Zhu, Y.C., GF Lv, FX Wang, XL Ji, X Xu, YH Sun, J Wu, L Zheng, YT Gao, GX, Proceedings of the National Academy of Sciences of the United States of America, 2011. 108(38): p. 15834-15839; ISI[ 000295030000038].
[WOS]. HIV_0930-101311.